Compare Abbott Laboratories (ABT) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Wahed FTSE USA Shariah ETF — how do they compare? Abbott Laboratories trades at $95.53 (market cap $166.94B), while Wahed FTSE USA Shariah ETF trades at $70.6. The key difference: Abbott Laboratories pays a 2.63% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | HLAL | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $73.60 |
52-Week Low | $82.57 | $53.83 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
HLAL trades at $71.16, up 1.22% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $71-$73, with support at $70 and $69. Recent dividend activity includes a $0.02 distribution scheduled for June 2026, though key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity.
The outlook remains cautious due to weak technical momentum and lack of recent financial data. Risks include market volatility and potential earnings uncertainty, while opportunities hinge on future corporate updates. Investors should await fresh earnings reports for a clearer valuation picture amid current bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
